WHAT'S UP IN

Neu!

Pegram Excited for Additional Advances in HER2+ Breast Cancer

By:The Tutu Team | 31st October 2016

Mark Pegram, MD Though some clinicians may characterize the treatment landscape of HER2-positive...

By:The Tutu Team | 20th October 2016

Before sunrise on February 22, 2013, Alexander Hardy, a Genentech vice president at the time, was...

By:The Tutu Team | 14th October 2016

Researchers are reporting clinical activity with the investigational oral compound tucatinib, used...

By:The Tutu Team | 11th October 2016

Over the last decade, scientists have come to realize there is no one breast cancer. It’s...

By:The Tutu Team | 10th October 2016

You are here: Home » News » Industry news » Novartis’ HR+/HER2- advanced...